Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: G04BD10

Emselex(darifenacin hydrobromide)

Urinary Incontinence, Urge;Urinary Bladder, Overactive

Marketing Authorisation Holder: pharmaand GmbH

EMA Authorisation: 22/10/2004

INN: darifenacin hydrobromide

Indication

Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Emselex — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.